Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Raw Materials (2016 - 2025)

Adma Biologics (ADMA) has disclosed Raw Materials for 10 consecutive years, with $96.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Raw Materials rose 59.76% year-over-year to $96.6 million, compared with a TTM value of $96.6 million through Dec 2025, up 59.76%, and an annual FY2025 reading of $96.6 million, up 59.76% over the prior year.
  • Raw Materials was $96.6 million for Q4 2025 at Adma Biologics, up from $87.8 million in the prior quarter.
  • Across five years, Raw Materials topped out at $100.4 million in Q2 2025 and bottomed at $33.1 million in Q2 2021.
  • Average Raw Materials over 5 years is $57.4 million, with a median of $53.0 million recorded in 2023.
  • The sharpest move saw Raw Materials increased 4.35% in 2023, then surged 76.14% in 2025.
  • Year by year, Raw Materials stood at $36.8 million in 2021, then soared by 32.34% to $48.6 million in 2022, then increased by 8.95% to $53.0 million in 2023, then rose by 14.1% to $60.5 million in 2024, then skyrocketed by 59.76% to $96.6 million in 2025.
  • Business Quant data shows Raw Materials for ADMA at $96.6 million in Q4 2025, $87.8 million in Q3 2025, and $100.4 million in Q2 2025.